Ritzmann Felix, Brand Michelle, Bals Robert, Wegmann Michael, Beisswenger Christoph
Department of Internal Medicine V-Pulmonology, Allergology and Respiratory Critical Care Medicine, Saarland University, 66421 Homburg, Germany.
Helmholtz Institute for Pharmaceutical Research, 66123 Saarbrücken, Germany.
Cells. 2025 Feb 10;14(4):251. doi: 10.3390/cells14040251.
Epigenetics regulates gene expression and thus cellular processes that underlie the pathogenesis of chronic lung diseases such as chronic obstructive pulmonary disease (COPD), asthma, and idiopathic pulmonary fibrosis (IPF). Environmental factors (e.g., air pollution, smoking, infections, poverty), but also conditions such as gastroesophageal reflux, induce epigenetic changes long before lung disease is diagnosed. Therefore, epigenetic signatures have the potential to serve as biomarkers that can be used to identify younger patients who are at risk for premature loss of lung function or diseases such as IPF. Epigenetic analyses also contribute to a better understanding of chronic lung disease. This can be used directly to improve therapies, as well as for the development of innovative drugs. Here, we highlight the role of epigenetics in the development and progression of chronic lung disease, with a focus on DNA methylation.
表观遗传学调控基因表达,进而影响细胞过程,而这些细胞过程是慢性肺病(如慢性阻塞性肺疾病、哮喘和特发性肺纤维化)发病机制的基础。环境因素(如空气污染、吸烟、感染、贫困)以及胃食管反流等情况,早在肺部疾病被诊断之前就会引发表观遗传变化。因此,表观遗传特征有潜力作为生物标志物,用于识别有肺功能过早丧失风险的年轻患者或患有特发性肺纤维化等疾病的患者。表观遗传分析也有助于更好地理解慢性肺病。这可直接用于改善治疗方法,以及开发创新药物。在此,我们重点强调表观遗传学在慢性肺病发生和发展中的作用,尤其关注DNA甲基化。